| Title |
Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives
|
|---|---|
| Published in |
Vascular Health and Risk Management, September 2017
|
| DOI | 10.2147/vhrm.s130338 |
| Pubmed ID | |
| Authors |
Alberico Luigi Catapano, Angela Pirillo, Giuseppe Danilo Norata |
| Abstract |
Heterozygous familial hypercholesterolemia (FH) is a genetic disorder characterized by high low-density lipoprotein cholesterol levels from birth, which exposes the arteries to high levels of atherogenic lipoproteins lifelong and results in a significantly increased risk of premature cardiovascular events. The diagnosis of FH, followed by an appropriate and early treatment is critical to reduce the cardiovascular burden in this population. Phase I-III clinical trials showed the benefit of proprotein convertase subtilisin kexin 9 inhibitors, both alirocumab and evolocumab, in these patients with an average low-density lipoprotein cholesterol reduction ranging from -40% to -60%. The aim of this review is to address the unmet needs in cholesterol management, elucidate the biology and the clinical benefit of proprotein convertase subtilisin kexin 9 inhibition and finally discuss the open gaps and future directions in the treatment of patients with heterozygous FH. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 67 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 11 | 16% |
| Researcher | 10 | 15% |
| Student > Bachelor | 7 | 10% |
| Student > Doctoral Student | 6 | 9% |
| Other | 6 | 9% |
| Other | 15 | 22% |
| Unknown | 12 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 30% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 13% |
| Agricultural and Biological Sciences | 8 | 12% |
| Biochemistry, Genetics and Molecular Biology | 5 | 7% |
| Immunology and Microbiology | 2 | 3% |
| Other | 4 | 6% |
| Unknown | 19 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 September 2017.
All research outputs
#20,663,600
of 25,382,440 outputs
Outputs from Vascular Health and Risk Management
#675
of 804 outputs
Outputs of similar age
#251,382
of 324,453 outputs
Outputs of similar age from Vascular Health and Risk Management
#9
of 10 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 804 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one is in the 7th percentile – i.e., 7% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,453 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one.